Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5004 in Chinese participants with overweight/obesity with or without type 2 diabetes
NCT06988553Phase 1Completed
- Sponsor
- Eccogene
- Start
- Jun 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing AZD5004 with Placebo (2 arms). Primary endpoints: Adverse Events at 16 weeks, Serious Adverse Events at 16 weeks and 6 more. Started Jun 2025; status: completed.
02
Drugs
elecoglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06988553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06988553.